Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBIT (2016 - 2025)

Historic EBIT for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$94.9 million.

  • Iovance Biotherapeutics' EBIT fell 655.13% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$416.5 million, marking a year-over-year increase of 313.66%. This contributed to the annual value of -$395.3 million for FY2024, which is 1417.43% up from last year.
  • Iovance Biotherapeutics' EBIT amounted to -$94.9 million in Q3 2025, which was down 655.13% from -$113.8 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year EBIT high stood at -$86.6 million for Q4 2024, and its period low was -$121.3 million during Q4 2023.
  • For the 3-year period, Iovance Biotherapeutics' EBIT averaged around -$107.8 million, with its median value being -$110.9 million (2023).
  • As far as peak fluctuations go, Iovance Biotherapeutics' EBIT surged by 2860.06% in 2024, and later tumbled by 1163.73% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' EBIT stood at -$121.3 million in 2023, then grew by 28.6% to -$86.6 million in 2024, then dropped by 9.62% to -$94.9 million in 2025.
  • Its EBIT stands at -$94.9 million for Q3 2025, versus -$113.8 million for Q2 2025 and -$121.2 million for Q1 2025.